The story of Viagra, and its developer copyright, presents a intriguing case study for investors. Initially a blockbuster drug, yielding billions in revenue , its patent expiration created a deluge of lower-priced alternatives , significantly diminishing its market share . While some firms may try to capitalize on male sexual dysfunction, the curre